Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality.
about
Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trialPain assessment for people with dementia: a systematic review of systematic reviews of pain assessment tools.Resourse Use and Disease Couse in dementia - Nursing Home (REDIC-NH), a longitudinal cohort study; design and patient characteristics at admission to Norwegian nursing homes.Outpatient treatment of sleep disorders in Alzheimer patientsMovement disorders in elderly users of risperidone and first generation antipsychotic agents: a Canadian population-based studyFactors Related to Rejection of Care and Behaviors Directed towards Others: A Longitudinal Study in Nursing Home Residents with Dementia.The development and testing of the quality use of medications in dementia (QUM-D): a tool for quality prescribing for behavioral and psychological symptoms of dementia (BPSD).Clinical Predictors of Mortality in Adults with Intellectual Disabilities with and without Down Syndrome.Behavioral and Psychological Symptoms of Dementia and Antipsychotic Drug Use in the Elderly with Dementia in Korean Long-Term Care Facilities.Are commonly used psychoactive medications associated with lower urinary tract symptoms?Polypharmacy and inappropriate medication use in patients with dementia: an underresearched problem.Treatment-emergent adverse events associated with atypical antipsychotics.Are atypical antipsychotics safer than typical antipsychotics for treating behavioral and psychological symptoms of dementia?Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies.An Internet-Based Method for Extracting Nursing Home Resident Sedative Medication Data From Pharmacy Packing Systems: Descriptive Evaluation.Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.Impact of antipsychotic review and non-pharmacological intervention on health-related quality of life in people with dementia living in care homes: WHELD-a factorial cluster randomised controlled trial.Time trends in antipsychotic drug use in patients with dementia: a nationwide study.Determining the impact of psychosis on rates of false-positive and false-negative diagnosis in Alzheimer's disease."The Lesser of Two Evils" Versus "Medicines not Smarties": Constructing Antipsychotics in Dementia.Non-pharmacological interventions for managing dementia-related sleep problems within community dwelling pairs: A mixed-method approach.Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study.Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial.'There's a Catch-22' - The complexities of pain management for people with advanced dementia nearing the end of life: A qualitative exploration of physicians' perspectives.Barriers to antipsychotic discontinuation in nursing homes: an exploratory study.Silent lives: why do we fail community-dwelling people with dementia?General practitioners' knowledge, attitudes and experiences of managing behavioural and psychological symptoms of dementia: protocol of a mixed methods systematic review and meta-ethnography.Pharmacological and non-pharmacological treatment preferences of healthcare professionals and proxies for challenging behaviors in patients with dementia.PsychosisInterprovincial Variation of Psychotropic Prescriptions Dispensed to Older Canadian AdultsAssociations between risk of mortality and atypical antipsychotic use in vascular dementia: a clinical cohort study
P2860
Q28730154-02FF451A-3F85-4F24-876C-F1D28757FD9CQ30614326-4239198A-58CB-4D8F-B84D-3DA179507565Q33717331-3052DC8F-DBA0-461B-8A6C-AD5BF3D92EC5Q34669691-E9DCBBD3-C9F8-4BB9-8536-01F11E55224CQ34734083-E521196C-5F74-4C1E-A951-0D28E54535E8Q35631283-D6925ECC-3E4B-477D-A8D9-13A18314B66AQ35848943-34F82428-424D-4590-9263-AFBE830EA849Q35993696-9812EF21-A5AB-4A4F-B050-381277AEB6E4Q36360262-4CCDD96C-CABA-451D-9453-54DEC234AC45Q36513874-F04E1BA7-2A74-4880-B5D1-4DE6DC3DEAFFQ37632244-F4010B5A-D98D-4BA1-A24A-467D382D22B4Q37981271-E013FA0B-F0FE-4CA6-AF6B-96BB051F0044Q38015698-C1082F40-900A-46F7-B33A-403B6DB2096CQ38214498-D34D0336-B728-49B3-86E8-150E6CD1C765Q38639887-64ADB0B8-39FC-4D95-BAFA-5C6143CEC838Q38661735-B698F66C-D398-49B1-9756-6AB9D27A7FD0Q38957896-E494E080-BB33-4198-A493-18DBFD9C3CA9Q40457871-35FB7B52-52D3-4AC0-934D-DD8DBEF389ABQ42655543-25F28F28-86A5-418C-9D2B-2ABE955B4C9DQ47597487-A0B416DF-6AAE-4F63-8F94-41762866D279Q47898895-87E1556A-272B-4568-A31C-4AD336B0E6D3Q47899977-0F489BA9-B4C6-402F-B626-8C15D5451204Q48097486-379C834F-7766-4E00-8D4B-24CBE77A92F9Q48504456-590E6205-F47C-4A9B-9A8A-40974B7B194FQ49113515-B7B48269-FCE7-4CED-BB15-C7CD13CD4647Q51833078-98324F65-A8E6-4806-8E65-7BC06161A817Q52569138-2123FF30-571A-415C-8D37-6628D3C90F00Q53626464-27626704-326E-4DF2-A28C-ED5DD7A4138EQ56059688-62357B00-90E1-4D85-83E3-53661D27B540Q57063692-A7F4CC7F-1963-44A9-973C-82A753A8620FQ57916505-8B1CE95C-8617-4B85-8AA1-9FD931565F09
P2860
Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Atypical antipsychotics for th ...... r term outcomes and mortality.
@en
Atypical antipsychotics for th ...... r term outcomes and mortality.
@nl
type
label
Atypical antipsychotics for th ...... r term outcomes and mortality.
@en
Atypical antipsychotics for th ...... r term outcomes and mortality.
@nl
prefLabel
Atypical antipsychotics for th ...... r term outcomes and mortality.
@en
Atypical antipsychotics for th ...... r term outcomes and mortality.
@nl
P2860
P1476
Atypical antipsychotics for th ...... r term outcomes and mortality.
@en
P2093
Anne Corbett
Byron Creese
P2860
P356
10.1517/14740338.2010.506711
P407
P577
2010-08-05T00:00:00Z